Drug therapy problems among paediatric acute lymphoblastic leukaemia patients at Kenyatta National Hospital

Faith Jelagat Magut1, Amsalu Degu1

  • 1Department of Pharmaceutics and Pharmacy Practice, School of Pharmacy and Health Sciences, United States International University-Africa, Nairobi, Kenya.

Insights

Drug therapy problems (DTPs) are common in paediatric acute lymphoblastic leukaemia (ALL) patients. Adverse drug reactions were the most frequent DTP, highlighting the need for careful monitoring and management in this vulnerable population.

Area of Science:

  • Pharmacology
  • Oncology
  • Pediatrics

Background:

  • Drug therapy problems (DTPs) are frequently observed in cancer patients, potentially compromising treatment efficacy.
  • Identifying and addressing DTPs is crucial for optimizing therapeutic outcomes in oncology.

Purpose of the Study:

  • To investigate the prevalence, types, and predictors of DTPs in paediatric acute lymphoblastic leukaemia (ALL) patients.
  • To provide data for improving drug safety and patient care in this specific paediatric oncology setting.

Main Methods:

  • A retrospective cohort study design was employed.
  • Patient records from 2017-2021 at Kenyatta National Hospital were analyzed.
  • Binary logistic regression was used to identify predictors of DTPs.

Main Results:

  • A total of 82 DTPs were identified, with adverse drug reactions (ADRs) being the most common (72.0%).
  • Febrile neutropenia, nausea/vomiting, and anemia were the most frequent ADRs.
  • Central nervous system disease (AOR=10.2) and combined chemotherapy/radiotherapy (AOR=13.5) were significant predictors of DTPs.

Conclusions:

  • Paediatric ALL patients exhibit a high prevalence of DTPs, predominantly ADRs.
  • Central nervous system metastasis and combined treatment regimens are key risk factors for DTPs.
  • Findings underscore the importance of vigilant monitoring for DTPs in paediatric ALL management.

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...